OTCMKTS:NWPHF - Newron Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Newron Pharmaceuticals SpA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.50 0.00 (0.00 %) (As of 01/9/2020) Add Compare Today's Range$7.50Now: $7.50▼$7.5050-Day Range$7.50MA: $7.50▼$7.5052-Week Range$6.55Now: $7.50▼$7.50Volume40 shsAverage VolumeN/AMarket Capitalization$133.80 millionP/E RatioN/ADividend YieldN/ABeta0.21 ProfileAdvanced ChartHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:NWPHF Previous Symbol CUSIPN/A CIKN/A Webhttp://www.newron.com/ Phone39-02-6103-4630Debt Debt-to-Equity Ratio0.22 Current Ratio8.29 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.75 million Price / Sales28.17 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book2.07Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees24 Outstanding Shares17,840,000Market Cap$133.80 million Next Earnings Date3/3/2020 (Estimated) OptionableNot Optionable Receive NWPHF News and Ratings via Email Sign-up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter. OTC:NWPHF Rates by TradingView Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions What is Newron Pharmaceuticals' stock symbol? Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF." When is Newron Pharmaceuticals' next earnings date? Newron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Newron Pharmaceuticals. Has Newron Pharmaceuticals been receiving favorable news coverage? Press coverage about NWPHF stock has been trending neutral recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Newron Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Newron Pharmaceuticals. Who are some of Newron Pharmaceuticals' key competitors? Some companies that are related to Newron Pharmaceuticals include Axovant Sciences (AXON), CytoDyn (CYDY), Prothena (PRTA), Clovis Oncology (CLVS), Milestone Pharmaceuticals (MIST), Arcus Biosciences (RCUS), MacroGenics (MGNX), Satsuma Pharmaceuticals (STSA), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Magenta Therapeutics (MGTA), BioSpecifics Technologies (BSTC), Puma Biotechnology (PBYI), Ardelyx (ARDX) and Morphic (MORF). What other stocks do shareholders of Newron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Newron Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Celldex Therapeutics (CLDX), Abeona Therapeutics (ABEO), Alnylam Pharmaceuticals (ALNY), Aptinyx (APTX), Arrowhead Pharmaceuticals (ARWR), BioCryst Pharmaceuticals (BCRX), DBV TECHNOLOGIE/S (DBVT), Halozyme Therapeutics (HALO) and Intercept Pharmaceuticals (ICPT). Who are Newron Pharmaceuticals' key executives? Newron Pharmaceuticals' management team includes the folowing people: Mr. Stefan Weber, CEO & Exec. Director (Age 54)Mr. Roberto Galli, VP of Fin.Mr. Marco Caremi, Exec. VP of Bus. Devel. (Age 62)Dr. Ravi Anand, Chief Medical Officer (Age 62)Mr. Dennis Dionne, VP of Commercial Affairs (Age 69) How do I buy shares of Newron Pharmaceuticals? Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Newron Pharmaceuticals' stock price today? One share of NWPHF stock can currently be purchased for approximately $7.50. How big of a company is Newron Pharmaceuticals? Newron Pharmaceuticals has a market capitalization of $133.80 million and generates $4.75 million in revenue each year. The company earns $-17,760,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Newron Pharmaceuticals employs 24 workers across the globe.View Additional Information About Newron Pharmaceuticals. What is Newron Pharmaceuticals' official website? The official website for Newron Pharmaceuticals is http://www.newron.com/. How can I contact Newron Pharmaceuticals? Newron Pharmaceuticals' mailing address is Via Ludovico Ariosto 21, Bresso Mi, 20091. The company can be reached via phone at 39-02-6103-4630 or via email at [email protected] MarketBeat Community Rating for Newron Pharmaceuticals (OTCMKTS NWPHF)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 75 (Thanks for Voting!)Underperform Votes: 99 (Thanks for Voting!)Total Votes: 174MarketBeat's community ratings are surveys of what our community members think about Newron Pharmaceuticals and other stocks. Vote "Outperform" if you believe NWPHF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWPHF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: S&P/ASX 200 Index
